|Mr. Craig Kussman MBA||Chief Financial Officer||352.36k||N/A||1959|
|Dr. Sharon Collins Presnell Ph.D.||Chief Scientific Officer||479.56k||N/A||1969|
|Ms. Jennifer Kinsbruner Bush J.D.||Sr. VP, Gen. Counsel, Corp. Sec. & Compliance Officer||472.58k||N/A||1975|
|Mr. Taylor J. Crouch||CEO, Pres & Director||N/A||N/A||1960|
|Steve E. Kunszabo||VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
Organovo Holdings, Inc., an early commercial stage company, designs and creates functional and three-dimensional (3D) human tissues for use in medical research and therapeutic applications. The company develops 3D human tissue models through internal development and in collaboration with pharmaceutical, academic, and other partners. Its 3D human tissues could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company offers two commercial products, which include ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing a suite of standardized and 3D human tissues for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion, and drug metabolism and pharmacokinetics; customized human tissues as living, dynamic models of human biology, or disease for use in drug discovery and development, and disease modeling; and 3D human tissues for clinical applications, such as therapeutic liver tissue patch. Organovo Holdings, Inc. was founded in 2007 and is headquartered in San Diego, California.
Organovo Holdings, Inc.’s ISS Governance QualityScore as of April 1, 2018 is 4. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 5; Compensation: 6.